CRP Level Associated with The Severity Of COVID-19 Disease

Aso Hemn Omar; Darya Sardar Muhammadrasheed

doi:10.25212/lfu.qzj.8.2.41

المؤلفون

Aso Hemn Omar Department of Pathological Analytics, Paitaxt Technical Institute, Erbil - Kurdistan Region-IRAQ
Darya Sardar Muhammadrasheed Department of Medical Biology - Health Science Institute- Tokat- Gaziosmanpaşa University, Tokat-TURKEY.

DOI:

https://doi.org/10.25212/lfu.qzj.8.2.41

الكلمات المفتاحية:

CRP, IgG, IgM, COVID-19.

الملخص

The variables influencing the development of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in patients with coronavirus disease 2019 (COVID-19) are still unknown. The purpose of this study was to find these characteristics among COVID-19 patients who were recovering. Between January 15 and March 30, 2022, patients who were (investigated or examined) at Lalav Hospital were included in this study. 100 SARS-CoV-2-infected patients were all enrolled; 51% (51 cases) of the patients were female and 49% (49 cases) of the patients were male. Between the ages of 22 and 81. Sixty-one percent (61/100) of the patients had elevated CRP. P.Value (0.001). The severity of COVID-19 is positively correlated with serum CRP levels, and greater CRP levels were associated with longer hospital stays. For the first time, it is shown that CRP levels can help distinguish between patients with mild to moderate COVID-19 and those with more severe conditions.

التنزيلات

بيانات التنزيل غير متوفرة بعد.

المراجع

McCloskey B, Heymann DL. SARS to novel coronavirus–old lessons and new lessons. Epidemiol Infect. 2020; 148:e22.

Chen CC, Lee IK, Liu JW, Huang SY, Wang L. Utility of C-reactive protein levels for early prediction of dengue severity in adults. Biomed Res Int. 2015; 2015:936062.

Eppy E, Suhendro S, Nainggolan L, Rumende CM. The differences between interleukin-6 and c-reactive protein levels among adult patients of dengue infection with and without plasma leakage. Acta Med Indones. 2016;48(1):3–9.

Yacoub S, Wills B. Predicting outcome from dengue. BMC Med. 2014; 12:147. 7.

Diamond MS, Pierson TC. Molecular insight into dengue virus pathogenesis and its implications for disease control. Cell. 2015;162(3):488–92.

Pepys MB, Hirschfeld GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805–12.

Feng G, Zheng KI, Yan QQ, Rios RS, Targher G, Byrne CD, et al. COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies. J Clin Transl Hepatol. 2020;8(1):1–7. 10.

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20